Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced the results of two phase II trials in adults (studies 201 and 203) of the investigational amphetamine compound SPD465 (triple-bead mixed amphetamine salts [MAS]) at a major medical meeting of child and adolescent psychiatrists in San Diego, Calif. [click link for full article]
More...